PRT4165

Catalog No.S5315 Batch:S531501

Print

Technical Data

Formula

C15H9NO2
Molecular Weight 235.24 CAS No. 31083-55-3
Solubility (25°C)* In vitro DMSO 11 mg/mL (46.76 mM)
Ethanol 4 mg/mL (17.0 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.
Targets
Bmi1/Ring1A [1] BMI-1 [1]
(Cell-free assay)
3.9 μM 3.9 μM
In vitro PRT4165 is a potent inhibitor of PRC1-mediated H2A ubiquitylation in vivo and in vitro. It inhibits the accumulation of all detectable ubiquitin at sites of DNA double-strand breaks (DSBs), the retention of several DNA damage response proteins in foci that form around DSBs, and the repair of the DSBs. PRT4165 inhibits both RNF2 and RING 1A, which are partially redundant paralogues that together account for the E3 ubiquitin ligase activity found in PRC1 complexes, but not RNF8 nor RNF168. U2OS cells treated with increasing concentrations of PRT4165 show increasing numbers of cells in G2/M[2].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    HeLa cells

  • Concentrations

    50 μM

  • Incubation Time

    5 h

  • Method

    HeLa cells are transfected with Bmi1-FLAG, Ring1A and HA-ubiquitin. Twenty-four hours post transfection the cells are treated with either solvent (0.5% DMSO, 0.5% PEG400) or 50 μM PRT4165 for 5 hours. Bmi1-FLAG is immunoprecipitated from cell lysates, and conjugated ubiquitin is detected by Western-blot with anti-HA antibody.

Animal Study:[3]
  • Animal Models

    CD-1 mice

  • Dosages

    4 mg/kg and 8 mg/kg

  • Administration

    intraluminally injection

Selleck's PRT4165 has been cited by 5 publications

Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation [ Nat Commun, 2023, 10.1038/s41467-023-42930-y] PubMed: 37923799
Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish [ Leukemia, 2021, 10.1038/s41375-021-01121-8] PubMed: 33483612
Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish [ Leukemia, 2021, 10.1038/s41375-021-01121-8] PubMed: 33483612
TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner [ J Exp Clin Cancer Res, 2021, 40(1):195] PubMed: 34130705
Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming. [ Genome Res, 2019, 29(10):1659-1672] PubMed: 31515287

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.